, a cloning and sequencing study of the LMP1 gene was conducted in saliva and peripheral blood mononuclear cells (PBMCs) from 23 patients with IM at day 0 (D0) and day 180 (D180) after the onset of the disease. Multiple EBV strains were detected in 9 (39%) of the patients during follow-up, with 7 of 9 cases detected as early as D0. Six of the nine patients harbored the same dominant strain in saliva and PBMCs during follow-up, with a trend toward a restriction of the number of EBV strains in saliva but not in PBMCs at D180. Furthermore, transmission of a minor strain was observed between partners in a heterosexual couple. There was no correlation between multiple infections and EBV DNA load in either compartment.
To monitor multiple Epstein-Barr virus (EBV) infections during the early and convalescent stages of infectious mononucleosis (IM)
, a cloning and sequencing study of the LMP1 gene was conducted in saliva and peripheral blood mononuclear cells (PBMCs) from 23 patients with IM at day 0 (D0) and day 180 (D180) after the onset of the disease. Multiple EBV strains were detected in 9 (39%) of the patients during follow-up, with 7 of 9 cases detected as early as D0. Six of the nine patients harbored the same dominant strain in saliva and PBMCs during follow-up, with a trend toward a restriction of the number of EBV strains in saliva but not in PBMCs at D180. Furthermore, transmission of a minor strain was observed between partners in a heterosexual couple. There was no correlation between multiple infections and EBV DNA load in either compartment.
Epstein-Barr virus (EBV)-associated infectious mononucleosis
(IM) typically occurs in adolescents or young adults as a result of contact with infected saliva. EBV-associated IM is followed by lifelong persistence in resting memory B lymphocytes, associated with periodic release of infectious particles in saliva through lytic replication within the Waldeyer ring area (tonsils and adenoids) or in oral epithelial cells [1, 2] . This productive infection is thought to be the source of infection in EBV-naive individuals and to contribute to the persistence of EBV in an infected host through the periodic reinfection of B lymphocytes in the oral lymphoid tissue [3, 4] . The presence of several EBV types or EBV strains in a single host has been described in EBV-associated diseases in immunocompromised patients, in healthy EBV carriers, and, more recently, in patients with IM [5] [6] [7] . These multiple EBV infections are usually assessed by molecular studies of different EBV genes: the genes encoding EBV nuclear antigen (EBNA) 2 and EBNA3 are used to distinguish EBV type 1 from EBV type 2, and the gene encoding latent membrane protein 1 (LMP1) allows a further subdivision of the EBV types into different strains. Currently, at least 7 distinct EBV strains have been identified on the basis of LMP1 nucleotide sequence variation [8] . To date, the evolution of multiple EBV infections in oropharyngeal and blood compartments during IM remains unclear. In the present study, we performed a cloning and sequencing prospective study of the LMP1 gene in saliva and peripheral blood mononuclear cells (PBMCs) from patients with IM, to evaluate the frequency and evolution of EBV multiple infections during the acute and convalescent phases of IM.
Subjects, materials, and methods. Twenty-three previously healthy adults with clinically suspected IM were enrolled after confirmation of their diagnoses on the basis of the typical serological profile of acute EBV primary infection: presence of IgM with or without IgG antibodies against virus capsid antigen; lack of antibodies against EBNA; and presence of PaulBunnell heterophile antibodies, as assessed by an agglutination test. The average delay between the onset of IM symptoms and inclusion into the study (i.e., day 0 [D0]) was 2 days (range, 0-4 days). No antiviral treatment was used during the entire follow-up period. Details on the patients have been published elsewhere [9] . The study was approved by the Grenoble medical ethics committee (Comité Consultatif pour la Protection des Personnes en Recherche Biomédicale), and informed consent was obtained from all of the patients investigated.
EDTA peripheral blood and saliva samples were collected from patients with IM at D0 (date of the first day of consultation) and day 180 (D180) for LMP1 sequencing. A fragment of the LMP1 carboxy-terminal sequence (EBV nt 168130-168389) was amplified by polymerase chain reaction (PCR), using the primer set LMP1 (forward, GCGACTCTGCTGGAAATGAT; reverse, GACATGGTAATGCCTAGAAG). The primers were designed by use of Oligo software (version 6.1; MedProbe). PCR products visible on an ethidium bromide-stained agarose gel were cloned by use of the TOPO TA cloning kit (Invitrogen). Ten clones from To determine the sensitivity of this genotyping assay, we mixed a clone from the B95-8 cell line and a clone from the AG876 cell line possessing the 30-bp deletion in the LMP1 gene in various ratios, ranging from 1:1 to 1:100. PCR amplification, cloning, and sequencing were performed at each ratio. The results showed that sequencing of 10 clones/sample could detect coinfecting EBV genotypes present in vivo at a ratio of 1:20 (5%).
To correlate single or multiple EBV infections with EBV DNA load, quantitative measurements of EBV DNA loads in saliva and PBMC samples were performed as described elsewhere [9] , using the LightCycler real-time quantitative PCR (Roche Diagnostics). The data were analyzed by use of the Kruskal-Wallis test with the Statview J software package (version 4.02; Abacus Concepts).
Results. At D0, a single strain was identified in the saliva from 19 of 23 patients and in the PBMCs from 17 of 22 patients. In total, multiple EBV infections in saliva and/or PBMCs were present for 7 (30%) of 23 patients at D0 (P2, P10, P11, P12, P13, P15, and P17) (table 1) . P2, P11, P12, and P15 still had multiple EBV infections at D180, with an additional strain in PBMCs at D180 for P2. Furthermore, 2 patients (P20 and P21) with a single detectable strain in PBMCs at D0 also showed the presence of additional strains in PBMCs at D180. Conversely, P10, P13, and P17 showed a trend toward having the same single strain in saliva and PBMCs at D180. Overall, 9 (39%) of 23 patients showed multiple infections at least once during follow-up, with as many as 4 different strains in a single host. The frequencies of multiple EBV infections in saliva and in PBMCs were similar at D0: 44% (4/9) and 62% (5/8), respectively. At D180, multiple infections were detected less frequently in saliva than in PBMCs: 22% (2/9) and 67% (6/9), respectively. The cloning strategy allowed us to estimate the relative amount of each strain during multiple EBV infections. Six (67%) of 9 patients always harbored the same dominant strain in saliva and PBMCs at D0 and D180; the 3 other patients harbored a different dominant strain in saliva and PBMCs either at D0 (1 patient) or at D180 (2 patients).
Four previously published EBV strains were found among the 23 subjects: the B95-8 prototype strain (detected in 12 patients), the China 1 strain (Ch1, detected in 16 patients), the Mediterranean strain without deletion (MedϪ, detected in 8 patients), and the North Carolina strain (NC, detected in 1 patient). In addition, a new strain named "Gre" (GenBank accession no. AY615890) was detected in saliva and PBMCs from P2 and represented the dominant strain in both com- 
Changes in the amino acids in relation to the prototype sequence are shown in the table; ellipses indicate that there was no change relative to the prototype sequence, and dashes indicate the 30-bp deletion. Bold type indicates the signature amino acid changes that distinguish EBV strains, named in the last column in accordance with Edwards et al. [8] : Ch1, China 1 strain; MedϪ, Mediterranean strain without the 30-bp deletion. All EBV strains detected in the patient's partner were detected in the patient; however, the dominant strain detected in the partner's saliva (Ch1) was not the same as the dominant strain detected in the patient (MedϪ).
partments during follow-up. The Gre strain showed 6 amino acid changes: Q322D, Q334R, L338S, H352S, G355V, and S366A. Finally, there was no statistical correlation between single or multiple EBV infection and the EBV DNA load in PBMCs or saliva ( and , respectively) [9] . P p .51 P p .89 We were able to enroll the partner of P20 for the LMP1 genotyping assay on the day that P20 was included in the study. The partner had no history of IM but was EBV seropositive and had met P20 2 months earlier. Three different strains were detected in the partner's saliva: Ch1 (60%), B95-8 (20%), and MedϪ (10%), whereas only 1 of these strains (MedϪ) was detected in the saliva and PBMC samples from P20 at D0 (table  2) . At D180, the profile in the saliva from P20 had not changed, but the Ch1 and B95-8 strains appeared in the patient's PBMCs even though the dominant strain was still MedϪ. At D180, the EBV DNA loads in blood and saliva from the partner were undetectable, and the sequencing assays failed.
Discussion. To our knowledge, only 1 study has reported a follow-up of the pattern of concomitant infection with several EBV strains during the course of IM [6] . Here, we prospectively assessed the presence of different EBV strains in saliva and PBMCs by cloning and sequencing the LMP1 gene of 23 patients, sampled at D0 and D180 after the onset of IM. Multiple EBV infections were detected during follow-up in 9 (39%) of 23 patients with IM, and 7 (77%) of these 9 multiple EBV infections were detected during the early phase of IM. In patients with multiple EBV infections, as many as 4 different EBV strains were detected in a single host; the same EBV strains were often detected in both the saliva and the blood samples, although there was a trend toward a restriction of the number of EBV strains in saliva-but not in PBMCs-between D0 and D180.
Using a different strategy based on a nested PCR and heteroduplex tracking assay, Sitki-Green et al. [5, 6] found that 93% of patients with IM harbored multiple EBV infections, detectable in saliva, PBMC, or plasma samples. As many as 6 different strains were detected in a single individual. In the study by Sitki-Green et al., most of the patients were examined within 3 months after the onset of IM; only 4 patients were examined after 6 months. These discrepancies could be due to a specific epidemiological distribution or to a difference in the number of samples and time of sampling but are more likely attributable to the different methods used to detect EBV variants. Using the same cloning and sequencing strategy as in our study, Walling et al. [7] found that 22% of healthy EBV carriers carried multiple EBV infections in blood and/or saliva, a result similar to ours in the convalescent patients with IM. Similarly, the same wide range of prevalence of multiple EBV infections in healthy EBV carriers has been reported-from 0% to 100%, depending on the genotyping strategy.
Although their frequencies may still be a matter of debate, multiple EBV infections clearly occur during the early phase of IM. The present study also showed a trend toward a restriction of the heterogeneity of EBV infection in saliva-but not in the blood-during the convalescent phase of IM. Because we recently demonstrated a persistent high load of infectious EBV in saliva, contrasting with a low EBV DNA load in PBMCs 6 months after the onset of the IM [9] , these data raise the possibility that the natural history of the convalescent phase of EBV infection is different in the 2 compartments. One hypothesis is that the presence of multiple EBV infections in B lymphocytes, despite a low EBV DNA load, represents an advantage for the virus's lifelong persistence, whereas only the viruses most adapted to lytic replication in oropharyngeal tissues are released in saliva.
In the present study, our cloning and sequencing strategy allowed a relative quantification of the different strains present in a same compartment and showed that the same dominant strain was present in the oral cavity and PBMCs at D0 and D180 in two-thirds of the patients with multiple EBV infections. Furthermore, this strategy also allowed us to demonstrate that a healthy EBV carrier shedding multiple EBV genotypes can transmit a nondominant strain via the saliva. To our knowledge, the presence of a dominant strain in the majority of patients with multiple EBV infections and the possibility of transmission of a minor strain have not been described. With regard to this latter point, because of the long incubation period of IM (6-8 weeks), it is also possible that the minor strain found in the saliva of the donor at the time of the recipient's clinical presentation may have been, in fact, the major strain at the time of transmission. The presence and the meaning of dominant versus minor strains during IM should be analyzed in further studies, with the molecular analysis of more LMP1 clones at various phases of infection. In conclusion, the pattern of multiple EBV infections during IM is complex, with continuous trafficking of different strains probably modulated by the immunological responses within epithelial and lymphoid tissues of the oropharyngeal area, blood compartment, and other lymphoid tissues.
